Flodgren Gerd, O'Brien Mary Ann, Parmelli Elena, Grimshaw Jeremy M
Division of Health Services, Norwegian Institute of Public Health, Marcus Thranes gate 6, Oslo, Norway, 0403.
Cochrane Database Syst Rev. 2019 Jun 24;6(6):CD000125. doi: 10.1002/14651858.CD000125.pub5.
Clinical practice is not always evidence-based and, therefore, may not optimise patient outcomes. Local opinion leaders (OLs) are individuals perceived as credible and trustworthy, who disseminate and implement best evidence, for instance through informal one-to-one teaching or community outreach education visits. The use of OLs is a promising strategy to bridge evidence-practice gaps. This is an update of a Cochrane review published in 2011.
To assess the effectiveness of local opinion leaders to improve healthcare professionals' compliance with evidence-based practice and patient outcomes.
We searched CENTRAL, MEDLINE, Embase, three other databases and two trials registers on 3 July 2018, together with searching reference lists of included studies and contacting experts in the field.
We considered randomised studies comparing the effects of local opinion leaders, either alone or with a single or more intervention(s) to disseminate evidence-based practice, with no intervention, a single intervention, or the same single or more intervention(s). Eligible studies were those reporting objective measures of professional performance, for example, the percentage of patients being prescribed a specific drug or health outcomes, or both. We included all studies independently of the method used to identify OLs.
We used standard Cochrane procedures in this review. The main comparison was (i) between any intervention involving OLs (OLs alone, OLs with a single or more intervention(s)) versus any comparison intervention (no intervention, a single intervention, or the same single or more intervention(s)). We also made four secondary comparisons: ii) OLs alone versus no intervention, iii) OLs alone versus a single intervention, iv) OLs, with a single or more intervention(s) versus the same single or more intervention(s), and v) OLs with a single or more intervention(s) versus no intervention.
We included 24 studies, involving more than 337 hospitals, 350 primary care practices, 3005 healthcare professionals, and 29,167 patients (not all studies reported this information). A majority of studies were from North America, and all were conducted in high-income countries. Eighteen of these studies (21 comparisons, 71 compliance outcomes) contributed to the median adjusted risk difference (RD) for the main comparison. The median duration of follow-up was 12 months (range 2 to 30 months). The results suggested that the OL interventions probably improve healthcare professionals' compliance with evidence-based practice (10.8% absolute improvement in compliance, interquartile range (IQR): 3.5% to 14.6%; moderate-certainty evidence).Results for the secondary comparisons also suggested that OLs probably improve compliance with evidence-based practice (moderate-certainty evidence): i) OLs alone versus no intervention: RD (IQR): 9.15% (-0.3% to 15%); ii) OLs alone versus a single intervention: RD (range): 13.8% (12% to 15.5%); iii) OLs, with a single or more intervention(s) versus the same single or more intervention(s): RD (IQR): 7.1% (-1.4% to 19%); iv) OLs with a single or more intervention(s) versus no intervention: RD (IQR):10.25% (0.6% to 15.75%).It is uncertain if OLs alone, or in combination with other intervention(s), may lead to improved patient outcomes (3 studies; 5 dichotomous outcomes) since the certainty of evidence was very low. For two of the secondary comparisons, the IQR included the possibility of a small negative effect of the OL intervention. Possible explanations for the occasional negative effects are, for example, the possibility that the OLs may have prioritised some outcomes, at the expense of others, or that an unaccounted outcome difference at baseline, may have given a faulty impression of a negative effect of the intervention at follow-up. No study reported on costs or cost-effectiveness.We were unable to determine the comparative effectiveness of different approaches to identifying OLs, as most studies used the sociometric method. Nor could we determine which methods used by OLs to educate their peers were most effective, as the methods were poorly described in most studies. In addition, we could not determine whether OL teams were more effective than single OLs.
AUTHORS' CONCLUSIONS: Local opinion leaders alone, or in combination with other interventions, can be effective in promoting evidence-based practice, but the effectiveness varies both within and between studies.The effect on patient outcomes is uncertain. The costs and the cost-effectiveness of the intervention(s) is unknown. These results are based on heterogeneous studies differing in types of intervention, setting, and outcomes. In most studies, the role and actions of the OL were not clearly described, and we cannot, therefore, comment on strategies to enhance their effectiveness. It is also not clear whether the methods used to identify OLs are important for their effectiveness, or whether the effect differs if education is delivered by single OLs or by multidisciplinary OL teams. Further research may help us to understand how these factors affect the effectiveness of OLs.
临床实践并非总是基于证据,因此可能无法使患者获得最佳治疗效果。当地意见领袖(OLs)是被视为可信且可靠的个体,他们通过非正式的一对一教学或社区外展教育访问等方式传播和实施最佳证据。使用意见领袖是弥合证据与实践差距的一种有前景的策略。这是对2011年发表的一篇Cochrane系统评价的更新。
评估当地意见领袖在提高医疗专业人员对循证实践的依从性以及改善患者治疗效果方面的有效性。
我们于2018年7月3日检索了Cochrane中心对照试验注册库(CENTRAL)、医学期刊数据库(MEDLINE)、荷兰医学文摘数据库(Embase)以及其他三个数据库和两个试验注册库,同时检索了纳入研究的参考文献列表并联系了该领域的专家。
我们纳入了比较当地意见领袖单独或与一种或多种传播循证实践的干预措施联合使用的效果与无干预、单一干预或相同的一种或多种干预措施效果的随机对照研究。符合条件的研究是那些报告专业表现客观指标的研究,例如,开具特定药物的患者百分比或健康结局,或两者皆有。我们纳入了所有研究,无论用于识别意见领袖的方法如何。
我们在本系统评价中采用了标准的Cochrane程序。主要比较为:(i)任何涉及意见领袖的干预措施(单独的意见领袖、意见领袖与一种或多种干预措施联合使用)与任何对照干预措施(无干预、单一干预或相同的一种或多种干预措施)之间的比较。我们还进行了四项次要比较:ii)单独意见领袖与无干预,iii)单独意见领袖与单一干预,iv)意见领袖与一种或多种干预措施联合使用与相同的一种或多种干预措施,v)意见领袖与一种或多种干预措施联合使用与无干预。
我们纳入了24项研究,涉及超过337家医院、350家基层医疗诊所、3005名医疗专业人员和29167名患者(并非所有研究都报告了这些信息)。大多数研究来自北美,且均在高收入国家进行。其中18项研究(21项比较,71项依从性结局)用于主要比较的中位数调整风险差值(RD)分析。随访的中位时长为12个月(范围2至30个月)。结果表明,意见领袖干预措施可能会提高医疗专业人员对循证实践的依从性(依从性绝对提高10.8%,四分位间距(IQR):3.5%至14.6%;中等确定性证据)。次要比较的结果也表明,意见领袖可能会提高对循证实践的依从性(中等确定性证据):i)单独意见领袖与无干预:RD(IQR):9.15%(-0.3%至15%);ii)单独意见领袖与单一干预:RD(范围):13.8%(12%至15.5%);iii)意见领袖与一种或多种干预措施联合使用与相同的一种或多种干预措施:RD(IQR):7.1%(-1.4%至19%);iv)意见领袖与一种或多种干预措施联合使用与无干预:RD(IQR):10.25%(0.6%至15.75%)。单独的意见领袖或与其他干预措施联合使用是否能改善患者治疗效果尚不确定(涉及三项研究;五项二分法结局),因为证据的确定性非常低。对于两项次要比较,四分位间距包含了意见领袖干预措施可能产生小的负面影响的可能性。偶尔出现负面影响的可能解释例如意见领袖可能优先考虑了某些结局而牺牲了其他结局,或者基线时未考虑到的结局差异可能在随访时给人一种干预措施产生负面影响的错误印象。没有研究报告成本或成本效益。我们无法确定不同识别意见领袖方法的比较效果,因为大多数研究使用社会测量法。我们也无法确定意见领袖用于教育同行的哪些方法最有效,因为大多数研究对这些方法的描述很差。此外,我们无法确定意见领袖团队是否比单个意见领袖更有效。
单独的当地意见领袖或与其他干预措施联合使用,在促进循证实践方面可能有效,但研究内部和研究之间的效果存在差异。对患者治疗效果的影响尚不确定。干预措施的成本和成本效益未知。这些结果基于干预类型、研究背景和结局不同的异质性研究。在大多数研究中,意见领袖的角色和行为没有明确描述,因此我们无法对提高其有效性的策略进行评论。也不清楚用于识别意见领袖的方法对其有效性是否重要,或者由单个意见领袖还是多学科意见领袖团队进行教育效果是否不同。进一步的研究可能有助于我们理解这些因素如何影响意见领袖的有效性。